Key result
Chemotherapy showed no benefit over locoregional therapy alone for 5-year overall survival, progression-free survival, local recurrence, and distant recurrence in localized soft tissue sarcoma.
Why the study?
Does chemotherapy improve survival outcomes in patients with localized soft tissue sarcoma compared to locoregional therapy alone?
Meta-Analysis (n=3,157)
Does chemotherapy improve survival outcomes in patients with localized soft tissue sarcoma compared to locoregional therapy alone?
Chemotherapy does not appear to provide a survival benefit over locoregional therapy alone in patients with localized soft tissue sarcoma.
No OS or recurrence benefit with chemotherapy in localized STS; challenges routine adjuvant use and reinforces locoregional therapy as standard.
New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.
No takes yet. Share an insight, caveat, or question.
Istl et al. (2019) conducted a meta-analysis in Localized soft tissue sarcoma (n=3,157). Chemotherapy vs. Locoregional therapy alone was evaluated on 5-year OS, progression-free survival, LRFS, and DRFS. Chemotherapy showed no benefit over locoregional therapy alone for 5-year overall survival, progression-free survival, local recurrence, and distant recurrence in localized soft tissue sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: